BR112022007749A2 - TGF-B, MASKED CONSTRUCTION, TGF-B COMPLEX, MASKED TGF-B COMPLEX HETERODIMER, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE MASKED TGF-B CONSTRUCTS OR COMPLEXES, COMPOSITION, METHOD OF PRODUCTION OF A MASKED TGF-B CONSTRUCTION OR COMPLEX AND PHARMACEUTICAL COMPOSITION - Google Patents

TGF-B, MASKED CONSTRUCTION, TGF-B COMPLEX, MASKED TGF-B COMPLEX HETERODIMER, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE MASKED TGF-B CONSTRUCTS OR COMPLEXES, COMPOSITION, METHOD OF PRODUCTION OF A MASKED TGF-B CONSTRUCTION OR COMPLEX AND PHARMACEUTICAL COMPOSITION

Info

Publication number
BR112022007749A2
BR112022007749A2 BR112022007749A BR112022007749A BR112022007749A2 BR 112022007749 A2 BR112022007749 A2 BR 112022007749A2 BR 112022007749 A BR112022007749 A BR 112022007749A BR 112022007749 A BR112022007749 A BR 112022007749A BR 112022007749 A2 BR112022007749 A2 BR 112022007749A2
Authority
BR
Brazil
Prior art keywords
tgf
masked
complex
construction
complexes
Prior art date
Application number
BR112022007749A
Other languages
Portuguese (pt)
Inventor
D Seidel Ronald Iii
J Chaparro Rodolfo
F Ross John
Meng Low Chee
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Priority to BR122023021925-2A priority Critical patent/BR122023021925A2/en
Publication of BR112022007749A2 publication Critical patent/BR112022007749A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

CONSTRUTO DE TGF-? MASCARADO, COMPLEXO DE TGF-?, HETERODÍMERO DO COMPLEXO DE TGF-? MASCARADO, UM OU MAIS ÁCIDOS NUCLEICOS, USO DE UM OU MAIS CONSTRUTOS OU COMPLEXOS DE TGF-? MASCARADOS, COMPOSIÇÃO, MÉTODO DE PRODUÇÃO DE UM CONSTRUTO OU COMPLEXO DE TGF-? MASCARADO E COMPOSIÇÃO FARMACÊUTICA. A presente divulgação fornece construtos e complexos polipeptídicos do Fator de Crescimento Transformador Beta (TGF-ß) que encontram uso, por exemplo, no tratamento terapêutico de doenças incluindo doenças autoimunes. Também são descritos ácidos nucleicos que codificam os construtos e complexos e métodos de preparação dos construtos e complexos em sistemas de expressão baseados em células.CONSTRUCTION OF TGF-? MASKED, TGF-? COMPLEX, TGF-? COMPLEX HETERODIMER MASK, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE TGF-? MASKS, COMPOSITION, METHOD OF PRODUCTION OF A TGF-? MASK AND PHARMACEUTICAL COMPOSITION. The present disclosure provides Transforming Growth Factor Beta (TGF-ß) polypeptide constructs and complexes that find use, for example, in the therapeutic treatment of diseases including autoimmune diseases. Nucleic acids encoding the constructs and complexes and methods of preparing the constructs and complexes in cell-based expression systems are also described.

BR112022007749A 2019-10-23 2020-10-22 TGF-B, MASKED CONSTRUCTION, TGF-B COMPLEX, MASKED TGF-B COMPLEX HETERODIMER, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE MASKED TGF-B CONSTRUCTS OR COMPLEXES, COMPOSITION, METHOD OF PRODUCTION OF A MASKED TGF-B CONSTRUCTION OR COMPLEX AND PHARMACEUTICAL COMPOSITION BR112022007749A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023021925-2A BR122023021925A2 (en) 2019-10-23 2020-10-22 TGF-B COMPLEX, USES THEREOF, ONE OR MORE NUCLEIC ACIDS, COMPOSITION, METHOD FOR PRODUCING A MASKED TGF-B CONSTRUCTION OR COMPLEX, PHARMACEUTICAL COMPOSITION, METHOD FOR DELIVERY OF A TGF-B POLYPEPTIDE AND OPTIONALLY AT LEAST ONE MOD A POLYPEPTIDE CELLS THAT EXPRESS A TBR ON THEIR SURFACE MEMBRANE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962925227P 2019-10-23 2019-10-23
PCT/US2020/056937 WO2021081258A1 (en) 2019-10-23 2020-10-22 TGF-β POLYPEPTIDES

Publications (1)

Publication Number Publication Date
BR112022007749A2 true BR112022007749A2 (en) 2022-07-05

Family

ID=75620850

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022007749A BR112022007749A2 (en) 2019-10-23 2020-10-22 TGF-B, MASKED CONSTRUCTION, TGF-B COMPLEX, MASKED TGF-B COMPLEX HETERODIMER, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE MASKED TGF-B CONSTRUCTS OR COMPLEXES, COMPOSITION, METHOD OF PRODUCTION OF A MASKED TGF-B CONSTRUCTION OR COMPLEX AND PHARMACEUTICAL COMPOSITION
BR122023021925-2A BR122023021925A2 (en) 2019-10-23 2020-10-22 TGF-B COMPLEX, USES THEREOF, ONE OR MORE NUCLEIC ACIDS, COMPOSITION, METHOD FOR PRODUCING A MASKED TGF-B CONSTRUCTION OR COMPLEX, PHARMACEUTICAL COMPOSITION, METHOD FOR DELIVERY OF A TGF-B POLYPEPTIDE AND OPTIONALLY AT LEAST ONE MOD A POLYPEPTIDE CELLS THAT EXPRESS A TBR ON THEIR SURFACE MEMBRANE

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122023021925-2A BR122023021925A2 (en) 2019-10-23 2020-10-22 TGF-B COMPLEX, USES THEREOF, ONE OR MORE NUCLEIC ACIDS, COMPOSITION, METHOD FOR PRODUCING A MASKED TGF-B CONSTRUCTION OR COMPLEX, PHARMACEUTICAL COMPOSITION, METHOD FOR DELIVERY OF A TGF-B POLYPEPTIDE AND OPTIONALLY AT LEAST ONE MOD A POLYPEPTIDE CELLS THAT EXPRESS A TBR ON THEIR SURFACE MEMBRANE

Country Status (12)

Country Link
US (2) US11692018B2 (en)
EP (1) EP4034170A4 (en)
JP (1) JP2023500066A (en)
KR (1) KR20220087491A (en)
CN (1) CN114728072A (en)
AU (1) AU2020372413A1 (en)
BR (2) BR112022007749A2 (en)
CA (1) CA3155510A1 (en)
IL (1) IL292253A (en)
MX (1) MX2022004873A (en)
TW (1) TW202130655A (en)
WO (1) WO2021081258A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728072A (en) 2019-10-23 2022-07-08 库尔生物制药有限公司 TGF-beta polypeptides
CA3190579A1 (en) * 2020-08-27 2022-03-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068499A1 (en) 2004-01-06 2005-07-28 The Government Of The United States As Representedby The Secretary, Department Of Health & Human Services Compositions and methods for the high efficiency expression of the transforming growth factor-beta supergene family
SI1850873T1 (en) 2005-02-08 2019-05-31 Genzyme Corporation Antibodies to tgfbeta
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
WO2010096838A2 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proproteins and methods of use thereof
EP2401293B1 (en) 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
EP3798237A1 (en) * 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AU2014308751B2 (en) * 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
CN109311945A (en) 2016-03-02 2019-02-05 Cue生物制药公司 T cell modulability multimeric polypeptide and its application method
KR20240023201A (en) 2017-05-04 2024-02-20 악셀레론 파마 인코포레이티드 Tgf-beta receptor type ii fusion proteins and uses thereof
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP4321530A2 (en) * 2018-09-27 2024-02-14 Xilio Development, Inc. Masked cytokine polypeptides
CN114728072A (en) 2019-10-23 2022-07-08 库尔生物制药有限公司 TGF-beta polypeptides

Also Published As

Publication number Publication date
EP4034170A4 (en) 2023-06-07
EP4034170A1 (en) 2022-08-03
US11692018B2 (en) 2023-07-04
JP2023500066A (en) 2023-01-04
WO2021081258A1 (en) 2021-04-29
BR122023021925A2 (en) 2024-02-27
KR20220087491A (en) 2022-06-24
US20220372093A1 (en) 2022-11-24
CN114728072A (en) 2022-07-08
MX2022004873A (en) 2022-05-13
IL292253A (en) 2022-06-01
US20230416322A1 (en) 2023-12-28
CA3155510A1 (en) 2021-04-29
AU2020372413A1 (en) 2022-06-09
TW202130655A (en) 2021-08-16

Similar Documents

Publication Publication Date Title
BR112022007749A2 (en) TGF-B, MASKED CONSTRUCTION, TGF-B COMPLEX, MASKED TGF-B COMPLEX HETERODIMER, ONE OR MORE NUCLEIC ACIDS, USE OF ONE OR MORE MASKED TGF-B CONSTRUCTS OR COMPLEXES, COMPOSITION, METHOD OF PRODUCTION OF A MASKED TGF-B CONSTRUCTION OR COMPLEX AND PHARMACEUTICAL COMPOSITION
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
Di Donato et al. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells
BR112019011277A2 (en) polynucleotide, recombinant expression system, vector, polypeptide, recombinant cell, isolated synthetic immune receptor polypeptide or polypeptide heterodimer, immune effector cell or stem cell, immune or effector cell population, methods of manufacturing an immune effector cell that expresses sir, generating an RNA-modified cell population, providing anti-disease immunity and treating or preventing a disease, composition, use or method, kit, and amino acid sequence.
BR112018070741A2 (en) t cell receptor (tcr), tcr binding to a hla-a * 02 complex, tcr anti-cd3 fusion molecule, nucleic acid, expression vector, cell, purified and / or unnaturally occurring cell, and / or designed, pharmaceutical composition, method of treating a human subject in need thereof, injectable formulation for administration to a human subject, and method of producing a triple
CL2021003289A1 (en) CD3-binding antibodies. (request divisional 201900643)
BR112019006106A2 (en) cannabinoid loaded formulation, process for preparing the cannabinoid loaded formulation, pharmaceutical and nutraceutical compositions, and method of treating an individual suffering from a disease or disorder.
BR112018071585A2 (en) formulations of an lsd1 inhibitor
BR112019018307A2 (en) PLATFORM FOR IDENTIFICATION OF IMMUNOGENIC PEPTIDES BASED ON POPULATION
Zhang et al. Cerebral dopamine neurotrophic factor (CDNF) has neuroprotective effects against cerebral ischemia that may occur through the endoplasmic reticulum stress pathway
MX2020011257A (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications.
BR112017005531A2 (en) diaryl urea derivatives as p38 kinase inhibitors
AR116605A1 (en) BIFUNCTIONAL COMPOUNDS INCLUDING INSULIN PEPTIDES AND EGF (A) PEPTIDES
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
BR112018012951A2 (en) Phosphoramidate Nucleoside Drug Formulations
BR112022004972A2 (en) ANTIBODIES, ISOLATED NUCLEIC ACIDS, ISOLATED HOST CELLS, METHODS OF PRODUCTION OF AN ANTIBODY, OF PRODUCTION OF A BIESPECIFIC ANTIBODY, AND OF TREATMENT OF AN INDIVIDUAL, BIESPECIFIC ANTIBODIES, PHARMACEUTICAL COMPOSITION, ANTIBODY, BIESPECIFIC ANTIBODY OR PHARMACEUTICAL COMPOSITION OF THE ANTIBODY, USE OF A COMBINATION OF THE ANTIBODY AND METHODS TO REDUCE INFLAMMATION AND TO IMPROVE SCALING AND/OR SKIN ERUPTION AND COMBINATION FOR USE
BR112017013696A2 (en) peptides and their use in skin treatment
BR112022000382A2 (en) Administration of sting agonists and checkpoint inhibitors
BR112022011975A2 (en) MODIFIED INTERFERON-2 POLYPEPTIDE, MODIFIED GMOP-INTERFERON-2 POLYPEPTIDE, NUCLEIC ACID, PLASMID, VECTOR, CELL LINE, METHOD FOR PURIFICATION OF MODIFIED INTERFERON-2 POLYPEPTIDE, PHARMACEUTICAL COMPOSITION, METHOD FOR USE OF ONE OR MORE OF MODIFIED INTERFERON-¿2 POLYPEPTIDES AND METHOD TO TREAT A MEDICAL CONDITION IN AN INDIVIDUAL
Goswami et al. AVA-NP-695 selectively inhibits ENPP1 to activate STING pathway and abrogate tumor metastasis in 4T1 breast cancer syngeneic mouse model
Troncoso et al. Advantages in wound healing process in female mice require upregulation a2a-mediated angiogenesis under the stimulation of 17β-estradiol
Jurić et al. Expression of connexins 37, 43 and 45 in developing human spinal cord and ganglia
BR112022004941A2 (en) METHODS TO TREAT AUTOIMMUNE DISEASES WITH THE USE OF INTERLEUKIN-17 (IL-17) ANTAGONISTS
Ma et al. Direct reprograming of mouse fibroblasts into dermal papilla cells via small molecules
BR112016008086A2 (en) RECOMBINANT GLYCOPROTEINS AND THEIR USES

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023021925-2 PROTOCOLO 870230093261 EM 20/10/2023 15:54.